PI(A2) polymorphism and efficacy of aspirin

Lancet

Volumn 351, Issue 9111, 1998, Pages 1253-

  Cooke, Glen E ^b   Bray, Paul F ^b   Hamlington, Jeanette D ^b   Pham, Dung M ^b   Goldschmidt Clermont, Pascal J ^a  

^a Davis Heart and Lung Research Institute   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; FIBRINOGEN RECEPTOR; GLYCOPROTEIN IIIA; ANTITHROMBOCYTIC AGENT;

ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; DRUG MECHANISM; HEART INFARCTION; HUMAN; PRIORITY JOURNAL; PROTEIN POLYMORPHISM; THROMBOCYTE AGGREGATION; THROMBOEMBOLISM; DRUG EFFECT; GENETIC POLYMORPHISM; GENETICS; HETEROZYGOTE; HOMOZYGOTE; LETTER;

ASPIRIN; HETEROZYGOTE; HOMOZYGOTE; HUMANS; PLATELET AGGREGATION; PLATELET AGGREGATION INHIBITORS; PLATELET GLYCOPROTEIN GPIIB-IIIA COMPLEX; POLYMORPHISM, GENETIC;

EID: 0032565146     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(05)79320-X     Document Type: Article

References (5)

1. 1 Antiplatelet Trialists' Collaboration. Collaborative overview of randomised trials of antiplatelet therapy - I: prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. BMJ 1994; 308: 81-106.
2. 2 Weiss EJ, Bray PF, Tayback M, et al. A polymorphism of a platelet glycoprotein receptor as an inherited risk factor for coronary thrombosis. N Engl J Med 1996; 334: 1090-94.
3. 3 Feng D, Lindpainter K, Larson M, et al. Increased platelet aggregability associated with platelet GPIIa P1A2 polymorphism. Circulation 1997; 96: I-412a.
4. 4 Carter AM, Ossei-Gerning N, Wilson IJ, Grant PJ. Association of the platelet P1(A) polymorphism of glycoprotein IIb/IIIa and the fibrinogen Bβ 448 polymorphism with myocardial infarction and extent of coronary artery disease. Circulation 1997; 96: 1424-31.
5. A1/A2 polymorphism of platelet glycoprotein IIIa and risks of mycardial infarction, stroke, and venous thrombosis. Lancet 1997; 349: 385-88.